MX2022003704A - Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. - Google Patents
Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos.Info
- Publication number
- MX2022003704A MX2022003704A MX2022003704A MX2022003704A MX2022003704A MX 2022003704 A MX2022003704 A MX 2022003704A MX 2022003704 A MX2022003704 A MX 2022003704A MX 2022003704 A MX2022003704 A MX 2022003704A MX 2022003704 A MX2022003704 A MX 2022003704A
- Authority
- MX
- Mexico
- Prior art keywords
- htt
- antibodies
- human
- derived anti
- huntingtin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Abstract
Se proporcionan novedosos anticuerpos anti-huntingtina (HTT) derivados de humano y los derivados biotecnológicos de los mismos, de preferencia capaces de enlazarse a las especies mutadas y/o aglomeradas de huntingtina (HTT), y/o los fragmentos de los mismos, así como los métodos relacionados con los mismos. Los anticuerpos anti-huntingtina (HTT) derivados de humano y los derivados biotecnológicos se pueden utilizar en composiciones farmacéuticas y de diagnóstico par a la inmunoterapia de la enfermedad de Huntington dirigida a la huntingtina (HTT), y para el diagnóstico de la misma.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14179004 | 2014-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003704A true MX2022003704A (es) | 2022-04-26 |
Family
ID=51225442
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017001285A MX2017001285A (es) | 2014-07-29 | 2015-07-29 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
MX2022003704A MX2022003704A (es) | 2014-07-29 | 2017-01-27 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
MX2022003706A MX2022003706A (es) | 2014-07-29 | 2017-01-27 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017001285A MX2017001285A (es) | 2014-07-29 | 2015-07-29 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003706A MX2022003706A (es) | 2014-07-29 | 2017-01-27 | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (3) | US10556946B2 (es) |
EP (2) | EP3174898A2 (es) |
JP (3) | JP2017522886A (es) |
KR (1) | KR102643395B1 (es) |
CN (2) | CN107074937B (es) |
AU (3) | AU2015295441B2 (es) |
CA (1) | CA2954738A1 (es) |
EA (1) | EA201790165A1 (es) |
IL (2) | IL250180A0 (es) |
MX (3) | MX2017001285A (es) |
WO (1) | WO2016016278A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
JP2017522886A (ja) * | 2014-07-29 | 2017-08-17 | ニューリミューン ホールディング エイジー | ヒト由来抗ハンチンチン(htt)抗体及びその使用 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
MX2020001855A (es) | 2017-08-22 | 2020-08-13 | Biogen Ma Inc | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides. |
TW202110878A (zh) | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
EP4041308A1 (en) | 2019-10-07 | 2022-08-17 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
US20230067811A1 (en) | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
CN111909265B (zh) * | 2020-08-25 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 一种结合破伤风毒素重链c端结构域的人源抗体及应用 |
CA3239708A1 (en) | 2021-12-03 | 2023-06-08 | Aubin MICHALON | Novel potency assay for antibody-based drugs and useful means therefor |
WO2024121347A1 (en) * | 2022-12-07 | 2024-06-13 | Alchemab Therapeutics Ltd | Anti-huntingtin antibodies |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2116280A1 (en) | 1993-03-05 | 1994-09-06 | Marcy E. Macdonald | Huntingtin dna, protein and uses thereof |
US6255455B1 (en) * | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
DE69834193T2 (de) | 1997-08-01 | 2007-04-19 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur bestimmung von amyloid-ähnlichen fibrillen oder proteinaggregaten |
JP4344138B2 (ja) * | 2001-02-15 | 2009-10-14 | ユニバーシティ オブ シカゴ | タンパク質の折り畳みに影響する薬剤の酵母スクリーニング |
US7375194B2 (en) * | 2002-01-28 | 2008-05-20 | California Institute Of Technology | Antibodies that bind to an epitope on the Huntington's disease protein |
AU2004239114B2 (en) * | 2003-05-14 | 2008-03-13 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
US20050226863A1 (en) * | 2003-11-20 | 2005-10-13 | Massachusetts Institute Of Technology | Single-domain antibodies and uses thereof |
KR20120017469A (ko) * | 2007-01-05 | 2012-02-28 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
US8022268B2 (en) * | 2007-06-11 | 2011-09-20 | The University Of Zurich | Transgenic animal model for alzheimer's disease |
EP2734234A4 (en) * | 2011-07-20 | 2015-01-28 | Medimmune Ltd | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF |
CA2913418C (en) * | 2013-05-29 | 2021-11-23 | Vybion, Inc. | Single chain intrabodies that alter huntingtin mutant degradation |
WO2016005545A1 (en) * | 2014-07-10 | 2016-01-14 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington's disease |
ES2660372T3 (es) * | 2014-07-10 | 2018-03-22 | Affiris Ag | Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington |
JP2017522886A (ja) | 2014-07-29 | 2017-08-17 | ニューリミューン ホールディング エイジー | ヒト由来抗ハンチンチン(htt)抗体及びその使用 |
-
2015
- 2015-07-29 JP JP2017504353A patent/JP2017522886A/ja active Pending
- 2015-07-29 CN CN201580040265.7A patent/CN107074937B/zh active Active
- 2015-07-29 EP EP15742303.9A patent/EP3174898A2/en not_active Withdrawn
- 2015-07-29 MX MX2017001285A patent/MX2017001285A/es unknown
- 2015-07-29 WO PCT/EP2015/067327 patent/WO2016016278A2/en active Application Filing
- 2015-07-29 AU AU2015295441A patent/AU2015295441B2/en active Active
- 2015-07-29 CN CN202110774704.4A patent/CN113651887A/zh active Pending
- 2015-07-29 CA CA2954738A patent/CA2954738A1/en active Pending
- 2015-07-29 EA EA201790165A patent/EA201790165A1/ru unknown
- 2015-07-29 US US15/323,784 patent/US10556946B2/en active Active
- 2015-07-29 KR KR1020177005723A patent/KR102643395B1/ko active IP Right Grant
- 2015-07-29 EP EP24174406.9A patent/EP4406549A2/en active Pending
-
2017
- 2017-01-18 IL IL250180A patent/IL250180A0/en unknown
- 2017-01-27 MX MX2022003704A patent/MX2022003704A/es unknown
- 2017-01-27 MX MX2022003706A patent/MX2022003706A/es unknown
-
2020
- 2020-02-07 US US16/784,645 patent/US11401325B2/en active Active
- 2020-06-02 JP JP2020096056A patent/JP7235939B2/ja active Active
- 2020-08-13 AU AU2020217427A patent/AU2020217427B2/en active Active
- 2020-08-16 IL IL276721A patent/IL276721A/en unknown
-
2022
- 2022-06-30 US US17/810,113 patent/US20220332808A1/en active Pending
-
2023
- 2023-01-19 JP JP2023006564A patent/JP2023052519A/ja active Pending
-
2024
- 2024-01-17 AU AU2024200315A patent/AU2024200315A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11401325B2 (en) | 2022-08-02 |
WO2016016278A2 (en) | 2016-02-04 |
IL276721A (en) | 2020-09-30 |
KR102643395B1 (ko) | 2024-03-11 |
US20200392217A1 (en) | 2020-12-17 |
CN113651887A (zh) | 2021-11-16 |
JP2023052519A (ja) | 2023-04-11 |
US20170166631A1 (en) | 2017-06-15 |
US10556946B2 (en) | 2020-02-11 |
EP3174898A2 (en) | 2017-06-07 |
KR20170036785A (ko) | 2017-04-03 |
AU2015295441B2 (en) | 2020-05-14 |
AU2020217427B2 (en) | 2023-10-19 |
AU2015295441A1 (en) | 2017-02-02 |
US20220332808A1 (en) | 2022-10-20 |
EP4406549A2 (en) | 2024-07-31 |
JP2017522886A (ja) | 2017-08-17 |
JP2021003100A (ja) | 2021-01-14 |
WO2016016278A3 (en) | 2016-03-24 |
JP7235939B2 (ja) | 2023-03-09 |
IL250180A0 (en) | 2017-03-30 |
MX2017001285A (es) | 2017-04-25 |
CN107074937B (zh) | 2021-07-27 |
CA2954738A1 (en) | 2016-02-04 |
NZ728372A (en) | 2021-11-26 |
MX2022003706A (es) | 2022-04-26 |
CN107074937A (zh) | 2017-08-18 |
AU2024200315A1 (en) | 2024-02-08 |
EA201790165A1 (ru) | 2017-07-31 |
AU2020217427A1 (en) | 2020-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003704A (es) | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. | |
PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
MX2017008819A (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
IL287607A (en) | Preparations, kits and methods for inducing acquired cellular resistance using inducible stress proteins | |
PH12017500489A1 (en) | Human-derived anti-dipeptide repeats (dprs) antibody | |
GB2541150A (en) | Improvements in and relating to sample collection | |
MX2023000204A (es) | Variantes de proteinas de union al factor h y metodos de uso de estas. | |
MX2017008096A (es) | Pestivirus. | |
MX2016013584A (es) | Parvovirus porcino. | |
MX2019013124A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
WO2015001013A3 (en) | Human anti-ifn-alpha antibodies | |
MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
MX2016012986A (es) | Composiciones y metodos para identificar especies de ehrlichia. | |
EP3096136A4 (en) | Composition, method for preparing sugar chain sample, and method for analyzing sugar chain | |
EP4328245A3 (en) | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations | |
EP3135763A4 (en) | Method for improving protein expression, and composition for protein expression | |
AU2021236446A1 (en) | CRISPR-Cas-related methods, compositions and components for cancer immunotherapy |